BioCorRx Inc. in Anaheim secured $4.2 million financing, including $940,000 in equity financing from nine investors and $1.7 million from Alpine Creek Capital, effective by March 24, a press release said.
The company received an initial $2.5 million from Alpine Creek last June.
The funding supports the company in its preclinical studies of BICX101, an injectable naltrexone product intended to treat substance abuse addiction, and to back sales and marketing of medication-assisted treatment BioCorRx Recovery Program, according to Lourdes Felix, chief financial officer and chief operating officer.
BioCorRx Inc. is a wholly owned subsidiary of Fresh Start Private Inc., which changed its name from Fresh Start Private Management Inc. in 2014.
